Value of Holter Monitoring in Predicting Long
The value of two reported and two new ambulatory electrocardiographic (Holter) criteria was studied in 80 patients taking amiodarone for refractory recurrent sustained ventricular tachycardia. In the 80 patients, the four Holter criteria were as follows: 1-85% or greater reduction of ventricular premature complexes and abolition of couplets and nonsustained ventricular tachycardia in 74 patients who had 10 or more ventricular preniature complexes/h, or any couplets or nonsustained ventricular tachycardia/24 hours at baseline; II-abolition of nonsustained ventricular tachycardia in 51 patients who had nonsustained ventricular tachycardia at baseline; 111-85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 64 patients who had 30 or more ventricular premature complexes/h at baseline; and IV-85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 73 patients who had 10 or more ventricular premature complexes/h at baseline. Amiodarone was judged effective in, respectively, 51 of 74, 44 of 51, 51 of 64 and 61 of 73 patients by criterion I, II, III or IV.
During the follow-up period (19 ± 20 months), there were 19 instances of recurrence of ventricular arrhythThe role of ambulatory electrocardiographic (Holter) monitoring in assessing the efficac y of amiodarone therap y in patient s with ventricular tachyc ardi as is still controversial. Some investigators (1-3) have reported good predictive values of Holter monitoring; others (4, 5) have reported poor values. These reported differences may be due to differences in patient group s and efficacy criteria in the various studies From by Holter criteria, however, had a recurrence of arrhythmia, suggesting insensitivity of these Holter criteria. At 24 months, the respective sensitivity of criteria I, II, III and IV was 53, 29, 50 and 47%, the specificity was 86,94,90 and 95% and the predictive accuracy was 73, 63, 75 and 76%.
Conclusions: I) Inefficacy of amiodarone therapy by Holter criteria predicts a poor outcome but efficacy does not preclude a poor outcome (insensitivity). 2) Criterion I is the most sensitive but the least specific. 3) Criterion II could be used in only 51 of 80 patients and is the least sensitive. 4) Criterion III (with a stricter entry criterion) could be used in fewer patients than criterion I or IV and accuracy is not better. 5) Criterion IV is the most specificand has the best predictive accuracy. 6) Further studies should be done to identify the predictor of arrhythmia recurrence in patients with Holter criteria of efficacy.
(J Am Coil CardioI1987;9:169-74) tients) or ventricular fibrillation (4 patients) refractory to conventional antiarrhythmic agents and mexiletine were studied. Sixty patients had coronary artery disease and 20 had cardiomyopathy. None of the arrhythmias were associated with acute myocardial infarction or remediable causes (such as hypokalemia, digitalis toxicity or drug-induced arrhythmia) . Patients with arrhythmias refractory to conventiona l nonexperimental drugs and mexiletine or with intolerable side effects from conventional drugs and mexiletine were entered into this study.
Ambulatory electrocardiographic monitoring. The detailed methods have been published (6) . Continuous 24 hour ambulatory electrocardiograms were recorded on an Avionics" 445 two-channel recorder. Analysis of the tape was done on a com puterized Cardio Data System" scanner. Total numbers of ventricular premature complexes, couplets and nonsustained ventricular tachycardia (:2:3 ventricular premature complexes at a rate of :2: 100 beats/min) were generated by the scanner. Accuracy of the system has been previously validated (6) . The accuracy of the count of total ventricular premature complexes was 96 .3 ± 3.7%, of couplets 93 .7 ± 6.7% and of ventricular tachycardia 96 .2 ± 5.8%. The results were verified by three of the investigators (S.K., L.W. , J.F.). Mean ventricular premature complexes/h or couplets/h were calculated by dividing total number of ventricular premature complexes or couplets by the number of hours recorded.
Efficacy criteria by ambulatory monitoring. For this study, four Holter efficacy criteria were used (Table I) . By Holter efficacy criterion I, amiodarone was considered effective when it resulted in 85% or greater reduction of ventricular premature complexes and abolition of couplets and nonsustained ventricular tachycardia in patients who had 10 or more ventricular premature complexes/hour or any couplets or nonsustained ventricular tachycardia/24 h on Holter monitoring at baseline (1). By criterion II, amiodarone was considered effective when it resulted in abolition of nonsustained ventricular tachycardias in patients who had nonsustained ventricular tachycardias at baseline (2) . By criterion III, amiodarone was considered effective when it resulted in 85% or greater reduction of ventricular premature complexes (1,7) and abolition of nonsustained ventricuiar tachycardia (2, 8) in patients who had 30 or more ventricular premature complexes/h at baseline (7, (9) (10) (11) (12) . By criterion IV, amiodarone was considered effecti ve when it resulted in 85% or greater reduction of ventricular premature complexes (1,7) and abolition of nonsustained ventricular tachycardia (2, 8) in patients who had 10 or more ventricular premature complexes at baseline (I) .
Study design. Informed consent was obtained from all patients for the monitoring study and administration of amiodarone. All patients had a baseline 24 hour ambulatory electrocardiogram at least 5 half-lives after discontinuation of all antiarrhythmic medications. Amiodarone was given orally twice daily in equally divided doses. All patients received a loading dose of amiodarone (939 ± 281 mg/day) for 16 ± 7 days followed by a maintenance dose of 360 ± 112 rng/day . An additional class IA antiarrhythmic agent was given in 19 patients . Holter monitoring was repeated and the efficacy of amiodarone was assessed by Holter criteria in all patients before discharge from the hospital. All patients were discharged on treatment with amiodarone and followed up by the arrhythmia service of this institution . The end point of follow-up was I) recurrence of sustained ventricular tachycardia or sudden death ; 2) other death; 3) discontinuation of the discharge regimen due to side effects; or 4) arrhythmia-free survival as of February 15, 1986. Statistical methods. Standard deviation (mean ± SO) was used as the index of dispersion of observed values . Kaplan-Meier's method was used to generate actuarial survival rates of each group. The differences between groups were tested by log-rank test for statistical significance. A two-tailed probability value of less than 0.05 was considered significant. The sensitivity, specificity, positive predictive value, negative predictive value and predictive accuracy were defined as follows: sensitivity = TP/(TP + FN), specificity = TN/(TN + FP), positive predictive value TP/(TP + FP), negative predictive value = TN/(TN + Without NSVT or couplets 6 NSVT = nonsustained ventricular tachycardia; VPCs = ventricular premature complexes.
Abbreviations as in Table I .
Data are expressed as mean value :t SO in 80 patients . Abbreviations as in Tabl e I. A., 60
.~40 tachycardiawere markedlyreduced compared with the baseline values (p < 0.00 I: ventricular prerriature complexes; p < 0.001: couplets; and p < 0.025: nonsustained ventricular tachycardias) ( Table 3) . Results of efficacy assessments by various Holter efficacy criteria in individual patients are shown in Table 4 .
Results of follow-up. The mean duration of follow-up was 18.6 ± 19.5 (SE = 2.4) months in all. There were 19 recurrences of arrhythmia or sudden deaths, 12 nonarrhythmic cardiac deaths and 4 deaths of noncardiac origin during the entire follow-up period. Twelve patients had a recurrence within 6 months after discharge and 15 patients had a recurrence within 12 months. No patients had a recurrence during the period between 12 and 24 months.
From the results of follow-up , actuarial arrhythmia-free survival rates werealsogenerated by the Kaplan-Meier method and the differences between patients with efficacy and inefficacy by each criterion were tested by the log rank test for statistical significance (Fig. I to 4) 
Results
Holter monitoring at baseline. At baseline beforeamiodarone therapy, 64 (80%) of the 80 patients had 30 or more ventricular premature cornplexes/h (group I), 9 (11%) had less than 30 but 10 or more ventricular premature complexes/h (group 2) and 7 (9%) had fewer than 10 ventricular premature complexes (group 3). Each group was further subdivided by the presence (A) or absence (B) of nonsustained ventricular tachycardia or couplets (Table 2) . By Holter criterion I, 74 of 80 patients (93%) (groups 1, 2, 3A and 3B) qualified for the assessment by Holter monitoring. By Holter criterion II, 51 patients (64%) (groups~A ,. 2A and 3A) qualified for the assessment by Holter momtonng. By Holter criterion III, 64 patients (80%) (group I) qualified for the assessment by Holter monitoring. By Holtercriterion IV, 73 patients (91%) (groups I and 2) qualified for the assessment by Holter monitoring. Mean ventricular premature complex/h, couplets/h and number of episodes of nonsustained ventricular tachycardia/24 h are shown in Table 3 .
Holter monitoring on amiodarone therapy. After amiodarone therapy, mean frequencies of ventricular premature complexes, couplets and nonsustained ventricular OL.------.l------::l---"'---t ricular premature complexes/h. They suggested that in patients with less frequent «30/h) ventricular premature complexes, even more marked reduction will be necessary to attribute the reduction to a drug effect. Others have also suggested that 30 or more ventricular premature complexes/h may be necessary for reliable Holter assessment (10) (11) (12) . These observations form the basis of Holter criterion III (9,13). Holter criterion IV was derived from criteria I, II and III. Holter criteria III and IV were never previously tested in patients taking amiodarone.
Data analysis and statistical methods. Different statistical methods were used in different studies cited in this report (1,2,4,5), making it difficult to compare the results of various studies. The value of the statistical methods used in some of these studies has also been questioned (14) . Sensitivity, specificity and predictive accuracy obtained from results during the entire follow-up period may not be valuable because there is no control for duration of follow-up (14) . To avoid the problems, We analyzed our data by several statistical methods used by others (1,2,4,5) and compared the values of various Holter monitoring criteria by each statistical method. We also determined sensitivity, specificity and predictive accuracy at 6, 12, 24 and 36 months as has been suggested (14) .
Qualification rates of various criteria. The "qualification rates" (defined as the proportion of patients who are qualified for the efficacy assessment by various criteria) of Holter criteria I, II, III and IV were 93, 64, 80 and 91%, respectively. In a significant number of patients, Holter criterion II or III cannot be used to assess efficacy.
Accuracy ofvarious criteria. Actuarial arrhythmia-free survival rates were significantly different between patients with amiodarone efficacy and inefficacy by each criterion used in this study. A significant number of patients with amiodarone efficacy by each Holter criterion, however, had a recurrence because of the insensitivity of each criterion. The sensitivity of Holter criterion I was the highest, but Table 5 . From the results of follow-up, sensitivity, specificity, positive predictive value, negative predictive value and predictive accuracy of each criterion were also generated and are shown in Tables 6 and 7 .
The sensitivity of Holter criteria I, II, III and IV at 12 months were 53, 29, 50 and 47%, respectively. Holter criterion II had the lowest sensitivity. A more stringent entry criterion (criterion III) (2::30 ventricular premature complexes/h at baseline instead of 2:: 10 ventricular premature complexes/h) did not improve sensitivity and the number of patients with false negative results (false efficacy) was similar to those by criterion I or IV. The specificity of Holter criteria I, II, III and IV at 12 months was 81, 87, 88 and 92%, respectively. Criterion I had the lowest and criterion IV the highest specificity. The negative predictive value at 12 months was the lowest by criterion II and the positive predictive value at 12 months was the lowest by criterion I. At 12 months, the predictive accuracy of criterion IV was the highest and that of criterion II was the lowest. This study suggests that in patients with recurrent refractory ventricular tachycardia taking amiodarone, alone or in combination with a class lA antiarrhythmic agent, I) inefficacy by all four Holter criteria used in this study is specific and predicts a poor outcome, but 2) efficacy by Holter criteria is insensitive and does not preclude a poor outcome.
Efficacy criteria. Holter efficacy criteria I and II in this study are the same as criteria used by others (1,2) who reported good predictive values of Holter monitoring in patients taking amiodarone. Morganroth et al. (7) reported that, because of spontaneous variability in arrhythmia frequency, only a greater than 83% reduction of ventricular premature complexes can be attributed to a drug effect at the 95% confidence level in patients with 30 or more ven- *p values by log-rank test.
173 only 53% at 12 months and its specificity and positive predictive value were the lowest. The sensitivity and negative predictive value of criterion II were the lowest. The sensitivity of criterion III, although one might expect it to be better in view of a more stringent entry criterion, was similar to that of Holter criteria I and IV. This suggests that, in patients taking amiodarone, 10 or more ventricular premature complexes/h at baseline may be adequate for Holter assessment as compared with 30 or more ventricular premature complexes/h at baseline (7) . Specificity, positive predictive value and predictive accuracy of Holter criterion IV were the highest while negative predictive value was similar to that of other criteria, Comparison with other studies. Mean loading dose and maintenance dose of amiodarone in this study and the timing of Holter monitoring during amiodarone therapy were similar to those of other studies (1, 2) . Efficacy rates by Holter criteria I and II in this study are similar to those of others (1,2). Marchlinski et al. (I) reported that 34 (62%) of 55 patients had efficacy by their criterion (Holter criterion I) as compared with 51 (69%) of 74 patients in our study.
Veltri et al. (2) reported that 34 (81%) of 42 patients had efficacy by their criterion (Holter criterion II) as compared with 44 (85%) of 51 in our study.
The results of follow-up of all patients in this study are somewhat better than those of other studies (1, 2) but within the range of previously reported data (2, (15) (16) (17) (18) . These findings may suggest that our study population and methods are probably similar to those of other studies.
Morady et al. (4) reported a poor predictive value of Holtermonitoring of patients on amiodarone therapy, whereas DiCarlo et al. (19) from the same laboratory reported a good predictive value of Holter monitoring. However, they did not report the results of Holter monitoring at baseline before therapy. Many patients (for example, 36% in our study) have negative results of Holter monitoring at baseline by their criterion and do not have nonsustained ventricular tachycardia even before therapy. Because a negative test after therapy in patients who had a negative test before Limitations of the study. Some patients in our study received an additional antiarrhythmic agent. Our results might have been different had we studied patients taking amiodarone alone. Many investigators (5, (20) (21) (22) , however, are using an additional antiarrhythmic agent in patients taking amiodarone, and antiarrhythmic efficacy in these patients is evaluated by Holter monitoring. For this reason, our study may be relevant to the clinical management of patients with ventricular tachycardias.
Conclusions. In patients with refractory ventricular tachycardia taking amiodarone, alone or in combination with a class lA agent, we conclude that I) inefficacy by Holter criteria predicts a poor outcome (specific); 2) efficacy by Holter criteria, however, does not preclude a poor outcome (insensitivity); 3) Holter criterion I is the most sensitive, the least specific with the lowest positive predictive value and is applicable to 93% of patients; 4) criterion II is the least sensitive with the lowest negative predictive value and is applicable to only 64% of patients; 5) criterion III, with a more stringent entry criterion, is applicable to fewer patients (80%) than is Holter criterion I or IV, but its sensitivity, specificity, predictive value and predictive accuracy are not better than those of criteria I and IV; 6) criterion IV is slightly less sensitive than criterion I but is the most specific and has the best positive predictive value and predictive accuracy; 7) criteria I and IV could be applied to more patients and appear to be better criteria, but their sensitivity is 53% or less; and 8) further studies should be done to identify the predictors of recurrence of arrhythmia in patients with Holter criteria of efficacy.
